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A B S T R A C T
In Alzheimer's disease (AD), defects in essential metabolic processes for energy supply and phospholipid
membrane function have been implicated in the pathological process. However, post-mortem investigations are
generally limited to late stage disease and prone to tissue decay artifacts. In vivo assessments of high energy
phosphates, tissue pH and phospholipid metabolites are possible by phosphorus MR spectroscopy (31P–MRS), but
so far only small studies, mostly focusing on single brain regions, have been performed. Therefore, we assessed
phospholipid and energy metabolism in multiple brain regions of 31 early stage AD patients and 31 age- and
gender-matched controls using 31P–MRS imaging. An increase of phosphocreatine (PCr) was found in AD pa-
tients compared with controls in the retrosplenial cortex, and both hippocampi, but not in the anterior cingulate
cortex. While PCr/inorganic phosphate and pH were also increased in AD, no changes were found for phos-
pholipid metabolites. This study showed that PCr levels are speciﬁcally increased in regions that show early
degeneration in AD. Together with an increased pH, this indicates an altered energy metabolism in mild AD.
1. Introduction
Alzheimer's disease (AD) is the main cause of dementia in the el-
derly, responsible for about half of the nearly 47 million dementia cases
worldwide (Report, 2015). Although the disease is deﬁned by the ac-
cumulation of amyloid beta plaques and neuroﬁbrillary tau tangles in
the brain (Braak and Braak, 1991), other pathological processes can be
identiﬁed such as oxidative stress, vascular dysfunction, and in-
ﬂammation (Akiyama et al., 2000; de la Torre, 2004; Markesbery,
1997). Additionally, defects in essential metabolic processes for energy
supply and membrane function have been implicated in AD (Lynn et al.,
2010; Nitsch et al., 1992).
The human brain is highly vulnerable to disturbances in energy
metabolism, due to its relatively large energy consumption. Previous
AD studies demonstrated alterations in global and cellular energy
metabolism. FDG-PET studies have shown glucose hypometabolism in
the retrosplenial cortex (RSC) and medial temporal lobe in people with
mild cognitive impairment (MCI) and AD patients, as well as in cog-
nitively normal carriers of the APOE ε4 allele (Nestor et al., 2003;
Pietrini et al., 2000; Reiman et al., 2001; Reiman et al., 2005). Fur-
thermore, the enzyme creatine kinase (CK), obtained from post-mortem
AD tissue, shows reduced activity compared with samples that are free
from neurological disease (Aksenov et al., 2000; David et al., 1998).
The CK reaction, key to balance brain energy metabolism, can quickly
replenish adenosine triphosphate (ATP) from the energy buﬀer phos-
phocreatine (PCr), when local energy demands suddenly increase
(Lowe et al., 2015). This reaction also enhances the eﬃciency of mi-
tochondrial oxidative phosphorylation (OXPHOS) by keeping adeno-
sine diphosphate (ADP) suﬃciently available (Schlattner et al., 2006)
and prevents acidiﬁcation by maintaining pH (for a review see
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Wallimann et al., 2011).
One of the earliest pathological changes in AD is synaptic dys-
function, which correlates well with cognitive dysfunction and disease
severity (Terry et al., 1991). Alterations in neuronal membrane com-
position, vital for synaptic transmission, have been linked to synaptic
dysfunction in AD (Pomponi et al., 2008). For instance, post mortem
studies found reduced levels of the major membrane components
phosphatidylcholine, phosphatidylethanolamine and phosphatidylino-
sitol (Nitsch et al., 1992; Pettegrew et al., 2001), as well as altered
activity of catabolic and anabolic enzymes, suggesting compensatory
metabolic changes to reduce the rate of neuronal membrane loss (Ross
et al., 1998).
High energy phosphates, such as ATP and PCr, and metabolites of
phospholipid membrane metabolism can be assessed in vivo by phos-
phorus magnetic resonance spectroscopy (31P–MRS). This technique
has been applied in AD (e.g. Forlenza et al., 2002; Mandal et al., 2012;
Pettegrew et al., 1994; Smith et al., 1995), but previous studies, es-
sentially focusing on single brain regions, were severely hampered by
small sample sizes and low spectral resolution, resulting in a wide
disparity in ﬁndings. Furthermore, diﬀerences in the control groups
that were used, in the brain regions that were studied and in the disease
stages and medication statuses of the patients, may have contributed to
apparent inconsistencies in the literature.
The aim of the current study was to investigate whether abnormal
phospholipid and energy metabolism can be detected non-invasively in
early stage AD patients by 31P MR spectroscopic imaging (31P–MRSI).
This investigation was designed to overcome the limitations of previous
studies. First, we performed the measurements at 3 T ﬁeld strength with
proton (1H) decoupling to increase spectral resolution and sensitivity.
Secondly, by applying 31P–MRS in a 3-dimensional imaging mode we
could investigate multiple brain regions simultaneously. We speciﬁcally
addressed regions that are of interest in AD, namely, the hippocampus,
the RSC, and the anterior cingulate cortex (ACC). Finally, we selected a
well-deﬁned drug-naïve patient group and an age- and gender-matched
control group.
2. Materials and methods
2.1. Subjects and design
All visits of patients and controls to the Radboud university medical
center (Nijmegen, the Netherlands) took place between 2012 and 2015.
Patients aged ≥50 years with a diagnosis of possible or probable AD
according to the revised National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer's Disease and
Related Disorders Association 2011 criteria (McKhann et al., 2011)
with evidence of the pathophysiological process (i.e. from structural
MRI or cerebrospinal ﬂuid biomarker assays) and with a minimum Mini
Mental State Examination (MMSE) score of 20, were recruited from the
hospital's memory clinic or by referral from regional hospitals. All AD
patients participated in a randomized controlled trial on the eﬀect of a
medical food on brain phospholipid metabolism (Rijpma et al., 2017;
Dutch Trial Register 3346). Only baseline data were used in the current
study. Healthy control subjects, age- and gender-matched to the AD
group, were screened by telephone before being invited to the clinic. All
subjects were drug-naïve for AD medication (cholinesterase inhibitors
and NMDA-antagonists) and were free from neurological or psychiatric
disorders (other than dementia, for the AD patients). Patients nor
healthy controls used nutritional supplements containing docosahex-
aenoic acid, eicosapentaenoic acid or> 200% of the recommended
daily allowance of vitamins B, C, or E. All subjects were screened for
MRI contra-indications before inclusion in the study.
Written informed consent was obtained from all subjects and from
the informal caregivers of the AD patients. The local ethics committee
reviewed and approved the protocol and the study was conducted in
accordance with the Declaration of Helsinki.
Medical history, medication use and MMSE were recorded from all
subjects, as well as date of birth, sex, ethnicity, smoking habits, alcohol
consumption, and family history of AD. Level of education was classi-
ﬁed according to Verhage (Verhage, 1964) (comparable with the In-
ternational Standard Classiﬁcation of Education) and categorized in
three groups: primary education or lower (low), junior vocational
training (middle), and senior vocational or academic training (high).
2.2. MR acquisition
MRI and MRS were performed on a Magnetom Tim Trio 3T MR system
(Siemens, Erlangen, Germany) with a dual-tuned 1H/31P volume head coil
(Rapid Biomedical, Wuerzburg, Germany). High resolution MR images
were acquired with a T1-weighted magnetisation-prepared rapid gradient-
echo sequence (TR=2300ms, TE=3.16ms, TI=1100ms, 15° ﬂip-
angle, 176 sagittal slices, slice-matrix size=256×256mm, slice thick-
ness=1mm, voxel-size=1×1×1mm, TA=6:25min).
31P-MR spectra were acquired with whole brain 3D MRSI (a pulse-
acquire sequence with 40° ﬂip-angle, acquisition delay of 0.7ms in-
cluding 0.3-ms gradient phase encoding time, 512ms acquisition
duration with WALTZ4 1H decoupling during the ﬁrst 256ms with
γB1=250Hz ensuring (γB1) 2 > (JPH)2, TR=2000ms, FOV
260×260×260 mm; matrix size= 10×10×10, acquisition time
13:08min). Prior to acquisition, an automatic procedure was applied to
optimize the magnetic ﬁeld homogeneity of a rectangular shim volume
maximizing brain coverage while bound by the skull. Subsequently, if
necessary, the ﬁeld homogeneity was further adjusted manually until a
value of< 25Hz was obtained for the full width at half maximum of
the absolute-value 1H MR water signal. K-space was sampled with a
weighted elliptical phase-encoding scheme with four averages. The
volume of interest was centered on the midline and parallel to the line
from the anterior commissure to the posterior commissure. Spatial post-
processing consisted of zeroﬁlling to a matrix size of 16× 16×16. The
nominal volume of the measured voxels is about 17.5 cm3, the eﬀective
voxel at 64% of the spatial response function has a spherical shape with
a volume of about 40 cm3 (Pohmann and von Kienlin, 2001).
2.3. MRS and MRI data analyses
Four regions of interest (ROI) were selected for analysis from the 3D
31P–MRSI data: ACC, RSC, and left and right hippocampus (HL and HR).
Guided by the T1-weighted images, the MRSI grid was shifted in the x, y
and z dimension to position voxels in the ROI's (by AR; Fig. 1). For the
ACC, a voxel was selected anterior to the genu of the corpus callosum,
with the inferior border aligned with the line from the anterior com-
missure to the posterior commissure (AC-PC line), and on the mid-
sagittal plane. For the RSC, a voxel on the midsagittal plane was se-
lected posterior to the splenium of the corpus callosum, with the
inferior border aligned with the AC-PC line. For the HL and HR, a voxel
was selected at the anterior end of each hippocampus, with the inferior
and lateral border of the voxel aligned with the inferior and lateral side
of the hippocampus.
The software package Metabolite Report (Siemens Healthcare,
Erlangen, Germany) was used for post-processing (i.e. 100ms ex-
ponential ﬁlter, zero-ﬁlling, phase correction, baseline correction) and
for automatic ﬁtting of the spectra in the time-domain using prior
knowledge appropriate for 31P MR spectra (own spectral data and from
de Graaf (2008)). Eleven well-resolved resonance peaks were ﬁtted: the
phospholipid metabolites phosphoethanolamine (PEth), phosphocho-
line (PCh), glycerophosphoethanolamine (GPEth) and glyceropho-
sphocholine (GPCh), the high-energy phosphorus molecules PCr, ATP
(α-ATP, β-ATP and γ-ATP), nicotinamide adenine dinucleotide (NAD
(H)) and inorganic phosphate (Pi), and membrane-bound phospholipid
(details of this procedure are described in the Appendix).
Both a quantitative evaluation of the ﬁtting results and a visual
quality control were performed. Quantitatively, only metabolite ﬁts
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with a Cramer–Rao lower bound of ≤30% were considered reliable.
Qualitatively, two MR spectroscopists (AR and MvdG) independently
checked the spectra by visual inspection of the original spectra and the
ﬁtting results. If a metabolite peak was visually present, and its ﬁt was
assigned to the correct resonance—giving a minimal residue in the
subtraction spectrum—the ﬁtting result was accepted.
The integral of each metabolite resonance was expressed as a
percent area of the total phosphorous signal in the corresponding
spectrum. Hereby, the data were normalized, and corrected for cere-
brospinal ﬂuid (CSF) content and thus for diﬀerences in local atrophy.
Phosphomonoesters (PME) were calculated from the sum of PEth and
PCh, phosphodiesters (PDE) from GPEth and GPCh and total ATP
(tATP) from the sum of α-ATP, β-ATP and γ-ATP. In addition, the ratios
PME/PDE, PE/GPE, PC/GPC and PCr/Pi were computed. Intracellular
pH was determined from the chemical shift diﬀerence between the PCr
and Pi resonance peaks (Petroﬀ et al., 1985).
The T1-weighted images were segmented into grey matter (GM),
white matter (WM) and CSF using automatic segmentation software (by
AR; SPM8, Welcome Trust Centre for Neuroimaging, London, UK;
VBM8, Structural Brain Mapping Group, Jena, USA). Binary tissue maps
(matrices) of GM, WM, CSF were convolved with the, digitally sampled,
mathematically-modelled three dimensional point-spread function of
the MRSI, using Matlab 2012b (The Mathworks, Inc., Matrick, MA), to
obtain theoretically correct values of the contribution of tissue type to
each ROI (each consisting of one MRS voxel). GM-to-WM ratio (GM/
WM) was calculated for each ROI for each subject.
2.4. Statistical analyses
Two-factorial mixed ANOVAs were used to test diﬀerences in tissue
content (GM, WM, and CSF) and GM/WM in each ROI between mild AD
patients and controls. Group and brain region (ROI) diﬀerences were
analyzed for each spectroscopy outcome parameter using a mixed
model with group (AD or control), sex, brain region and its interaction
with group as ﬁxed factors, considering brain region as a within subject
factor, and adjusting for age. An unstructured variance-covariance
matrix for brain region was selected. The group-by-brain region inter-
action was only kept in the model if p < 0.10. In the covariate analysis,
GM/WM in each ROI was added to the ﬁnal primary model of each
parameter, to investigate the eﬀect of tissue composition on the eﬀects
of group and brain region. Although the inclusion of GM/WM in the
ﬁnal model led to a small change (10–20%) in many parameter esti-
mates, this was mainly without a change in main and/or interaction
eﬀects. Therefore we report the primary model in tables and ﬁgures and
refer to the eﬀect of GM/WM only where it led to a change in the main
and/or interaction eﬀects, and with> 20% change in the parameter
estimates of group or brain region. Goodness of ﬁt was assessed by
comparing Bayesian Information Criteria (BIC) and homoscedasticity
and normality of residuals were assessed by visual inspection. Statistical
analyses were performed using SAS 9.2 Software for Windows (SAS
Institute Inc., Cary, NC, USAf). Statistical signiﬁcance was set at
p < 0.05 without correction for multiple testing.
3. Results
3.1. Subjects
A total of 33 mild AD patients and 35 healthy control subjects were
enrolled in the study and subjected to MRI and MRS measurements.
Two AD patients had MR spectra of low quality (due to severe motion
and a dental implant) and four control subjects were found to meet an
exclusion criterion during or after the visit (two subjects took nutri-
tional supplements, two subjects presented with structural neurological
damage from ischemic infarcts and trauma). Therefore, 31 AD patients
and 31 controls were included in the ﬁnal analysis. The groups were
similar with respect to age and gender (see Table 1 for subject char-
acteristics).
3.2. ROI tissue contribution
The interaction between group and brain region for GM and CSF
contributions to the total volume of each ROI was not signiﬁcant, but
GM and CSF diﬀered signiﬁcantly between groups, and between brain
regions (all p < 0.001). GM was lower and CSF was higher in AD pa-
tients than in healthy control subjects (mean % ± SD, GM:36.3 ± 4.7
vs. 40.5 ± 4.0; CSF: 22.5 ± 4.7 vs. 18.1 ± 3.5). overall, GM was
highest in the right hippocampus, followed by left hippocampus, and
then followed by equal amounts in RSC and ACC (data not shown). CSF
in RSC and ACC was higher than in both hippocampi. There was a
signiﬁcant interaction between group and brain region for WM
Fig. 1. Voxel selection of 31P MR spectra displayed on sagittal (left) and coronal (right) anatomical images: anterior cingulate cortex (blue), retrosplenial cortex (yellow), left and right
hippocampus (purple). The nominal voxel size is indicated by squares and an approximation of the eﬀective spherical voxel size is indicated by circles. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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(p=0.004) and GM/WM (p=0.021). WM was higher in AD patients
compared with controls in the right hippocampus (41.5 ± 3.0 vs.
40.0 ± 2.6), but not in the other brain regions. GM/WM was lower in
AD patients than in controls in ACC, and both hippocampi, but not in
RSC (data not shown).
3.3. MRS results
High quality MR spectra were obtained with well-resolved PME,
PDE, Pi, PCr and ATP signals for the brain regions evaluated in this
study (Fig. 2). The linewidth of PCr varied between 8 and 13 Hz in the
diﬀerent brain regions (ACC: mean ± SD 13.5 ± 3.3 Hz, RSC:
8.1 ± 2.6 Hz, HL: 11.2 ± 2.6 Hz, HR: 12.5 ± 3.0 Hz). We did not
observe a diﬀerence in the linewidth of PCr between AD and controls
(mean ± SD 11.5 ± 3.9 Hz and 11.1 ± 3.0 Hz, not tested). ROI tissue
contributions showed typical diﬀerences with lower GM and higher CSF
in AD patients compared with controls.
In the statistical analysis, the interaction between group and brain
region was kept in the model for PCr, γATP and βATP, because it sur-
vived our criterion of p < 0.10. For all other outcome parameters, the
interaction term had a p-value> 0.10 and was removed from the
model.
3.4. Diﬀerences in energy metabolites and pH between groups
A signiﬁcant interaction between group and brain region was found
for PCr, showing that normalized PCr signals were higher in mild AD
patients compared with healthy control subjects in the RSC (Least
Square (LS) mean diﬀerence=0.86, SEM=0.29, p=0.004), HL (LS
mean diﬀerence= 1.52, SEM=0.52, p=0.005) and HR (LS mean
diﬀerence=1.47, SEM=0.38, p < 0.001), but not in the ACC
(p=0.947) (Fig. 3A). The interaction between group and brain region
was not signiﬁcant for γATP and βATP. A main eﬀect of group was
found for PCr/Pi, showing that this ratio was higher in mild AD patients
compared with healthy controls (LS mean diﬀerence= 0.22,
SEM=0.11, p=0.046) (Fig. 3B). Also pH was increased in AD patients
compared with controls (LS mean diﬀerence=0.008, SEM=0.004,
p=0.032) (Fig. 3C). No group diﬀerences were found for γATP, βATP,
αATP, total ATP, Pi, and NAD(H) (all p > 0.05). For a summary of
group eﬀects see Table 2.
3.5. Diﬀerences in phospholipid metabolites between groups
No interaction or group diﬀerence between mild AD patients and
healthy control subjects were found for any of the phospholipid meta-
bolites (PEth, PCh, GPEtn, GPCh, PME, and PDE; Table 2) or their ratios
(PEth/GPEth, PCh/GPCh, and PME/PDE) (all p > 0.05).
3.6. Diﬀerences in phosphorus metabolites and pH between brain regions
Brain region signiﬁcantly aﬀected all outcome parameters (all
p < 0.05), except PCh and PME (p > 0.05). The normalized signals of
total ATP, αATP, βATP, γATP, NAD(H), PEth, GPEtn, GPCh, and PDE
were lower in the RSC than in the ACC and both hippocampi (all
p < 0.05), while the pattern was reversed for the ratios PCh/GPCh and
PME/PDE (p < 0.001). We found no diﬀerence between the left and
right hippocampus for any of the energy and phospholipid metabolites
or pH (p > 0.05), except for αATP (LS mean diﬀerence=0.65,
SEM=0.26, p=0.015). See Table 3 for an overview of the diﬀerences
between brain regions.
3.7. Inﬂuence of tissue content
In the covariate analysis GM/WMwas added to the ﬁnal model. This
did not change the eﬀects of group, brain region or the interaction
between group and brain region on PCr, Pi, total ATP, αATP, βATP,
γATP, NAD(H), pH or any of the phospholipid metabolite signals.
However, for PCr/Pi the main eﬀect of brain region was reduced to a
trend (p=0.062) and the parameter estimates changed substantially,
when GM/WM was included in the model. There was no change in the
eﬀect of group on PCr/Pi.
4. Discussion
In this study we acquired high-quality 31P-MRSI data of the brain in
a large group of mild AD patients and in a well-matched healthy elderly
population. High spectral resolution enabled us to gather information
on high-energy phosphates, as well as on speciﬁc phospholipid meta-
bolites. MR spectra of the four brain regions that are among the most
studied in AD were investigated and for the ﬁrst time, these areas were
measured simultaneously by 31P-MRSI. We detected increased phos-
phocreatine and pH, but no changes in phospholipid metabolite signals
in mild AD patients. Interestingly, the increase in PCr was observed in
the RSC and in the hippocampi, regions that both show early patholo-
gical changes in AD, but not in the ACC, a region known to be involved
in the disease at a later stage. This suggests that the PCr abnormality
expands across brain regions in a similar fashion as other AD patholo-
gies, such as tau (Braak and Braak, 1991). Furthermore, in both groups
pH, high energy phosphates, and most phospholipid metabolites dif-
fered across brain regions.
As in vivo human 31P MRS brain studies are nearly always per-
formed under signal saturating conditions, changes in T1 relaxation
time may aﬀect metabolite signal intensities (Longo et al., 1993). Al-
though we cannot exclude that such an eﬀect has contributed to the
increased PCr signal, it would require a rather drastic decrease in PCr's
T1 value from about 3 to 2 s. Moreover, no increases in PME and PDE
signals were detected, while those would be aﬀected more severely by a
T1 decrease (Klomp et al., 2008). A potential cause for relaxation en-
hancement is a higher brain iron accumulation in AD patients (Tao
et al., 2014), but this would increase the signal linewidth, which was
not observed. Thus, the most likely explanation for the increased PCr
signal is a higher tissue concentration of this compound.
Elevated PCr signals have been reported before for AD patients in
comparison with young controls (Mandal et al., 2012), but as PCr also
increases with age in healthy persons (Chiu et al., 2015; Forester et al.,
2010; Longo et al., 1993) it is unclear whether this ﬁnding was due to
an aging eﬀect. The current results showed increased PCr, and PCr/Pi,
in AD patients compared with elderly controls of the same age. In
contrast, two earlier studies showed a decrease in prefrontal PCr in
mild, but not severe, AD (Pettegrew et al., 1994) and decreased PCr/Pi
in the frontal lobe (Smith et al., 1995). However, these studies were
performed at 1.5 T with only surface coil localization and involved
small sample sizes.
As the concentration of high energy phosphates depends on the
Table 1
Subject characteristics.
AD
n=31
Controls
n= 31
Age 73.4 years (6.8) 73.5 years (6.3)
Gender (%) 13 males (42%) 15 males (48%)
MMSE 23.2 (2.0) 28.1 (1.4)
Time since AD diagnosis 1.6months [0.2–15.3] –
BMI 25.4 kg/m2 (3.8) 26.3 kg/m2 (4.5)
Educational level (low/middle/high) 9/16/6 4/9/18
Smoking (never/past/current) 13/17/1 6/22/3
≥1 relatives with AD (n) 19 7
MMSE, mini mental state examination; AD, Alzheimer's disease; BMI, body mass index.
Data are presented as mean (standard deviation) or median [range] unless otherwise
indicated.
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balance between energy production and energy utilization, increases in
steady state PCr levels and PCr/Pi reﬂect a redistribution in the content
of metabolites involved in the connected CK and ATPase pseudo-equi-
libria (Du et al., 2007). This may be the consequence of reduced utili-
zation of ATP (Forester et al., 2010), caused by synaptic dysfunction or
loss of other energy requiring functionalities (Chandrasekaran et al.,
1996; Rapoport et al., 1996). Although these changes are expected to
lower ATP production and thus PCr, the ﬁnal balance between reduced
energy production and consumption may still result in a higher PCr
level. To maintain equilibrium, the increased PCr should be accom-
panied by changes in the levels of other substrates of the CK reaction,
such as a higher ATP concentration. Previous studies reported an in-
crease in (γ)ATP (Mandal et al., 2012; Mecheri et al., 1997; Pettegrew
et al., 1994), although no alterations in ATP levels were found in the
current nor in several other studies (e.g. Forlenza et al., 2002; Gonzalez
et al., 1996; Smith et al., 1995). Alternatively, a higher PCr may result
from an increased total amount of cellular creatine (Cr). However, in
vivo measurements of total Cr content in MCI and AD patients provide
no clear evidence that Cr is increased in the disease (Graﬀ-Radford and
Kantarci, 2013; Tumati et al., 2013). Finally, decreases in ADP and/or
H+ concentration may accompany the PCr increase. Indeed, a slight
increase in pH was detected in mild AD patients, but it does not fully
compensate for the increase in PCr when equilibrium is assumed.
Changes in PCr levels have also been associated with decreased CK
activity in the AD brain (Forester et al., 2010; Mandal et al., 2012).
However, it is unlikely to be a direct eﬀect of this decrease as even in
cytosolic CK knockout mice the remaining CK activity (< 20%) is suf-
ﬁcient to preserve equilibrium (in 't Zandt et al., 2004). Clearly, a
strongly aﬀected reaction rate will aﬀect processes that require rapid
(local) energy supply, and a higher PCr level may represent a ﬂux
adaptation to this condition.
There is some evidence for involvement of PCr in processes beyond
the PCr-CK system. Since glutamate uptake by synaptic vesicles is sti-
mulated by PCr, independent of ATP or CK (Xu et al., 1996), increased
PCr may prevent glutamate excitotoxicity (Bender et al., 2005). Fur-
thermore, PCr may be able to bind to and stabilize phospholipid
membranes (Tokarska-Schlattner et al., 2005) and may function as an
osmolyte (Bothwell et al., 2001) and a neurotransmitter (Almeida et al.,
2006). In addition, diﬀerences in metabolite levels may be explained by
variations in tissue and cell type (Griﬃn et al., 2002; Urenjak et al.,
1993), although our results remained unchanged when adjusting for
grey and white matter. A prominent neuropathological feature in AD is
astrogliosis (Osborn et al., 2016). As this alters the neuron-to-glia ratio
within grey and white matter (Beach et al., 1989), it is possible that
morphological diﬀerences between AD patients and healthy aged con-
trols play a role in the alterations in PCr and pH. Furthermore, atrophy
may introduce slight diﬀerences in the brain area that the measured
volumes encompass, which eﬀect may not be entirely captured by
Fig. 2. Representative spectra from the anterior cingulate cortex (ACC), retrosplenial cortex (RSC), left hippocampus (HL) and right hippocampus (HR) of an Alzheimer's disease patient
(73 years old). Zero ﬁlling to 4096 data points and an 8 Hz Gaussian ﬁlter were applied for display purposes. PEth, phosphoethanolamine; PCh, phosphocholine; Pi, inorganic phosphate;
GPEth, glycerophosphoethanolamine; GPCh, glycerophosphocholine; MP, membrane phospholipids; PCr, Phosphocreatine; ATP, adenosine triphosphate; NAD(H), nicotinamide adenine
dinucleotide; ppm, parts per million.
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adjusting for grey and white matter. However, ROIs were placed such
that volume of the actual area of interest was maximized and the
measured signals are dominated by the reported brain regions of in-
terest.
Contrary to our expectation, we did not observe diﬀerences between
mild AD patients and controls in any of the phospholipid metabolites,
although preclinical and post-mortem studies show alterations in
membrane function and lipid composition in AD (Nitsch et al., 1992;
Ross et al., 1998). No previous in vivo studies have reported on PEth,
PCh, GPEth or GPCh, but several studies reported changes of their total
amounts, i.e. PME, PDE or their ratio, in AD (e.g. Forlenza et al., 2005;
Gonzalez et al., 1996; Mecheri et al., 1997), although others reported
no diﬀerences in these metabolites (Bottomley et al., 1992; Brown et al.,
1993; Murphy et al., 1993; Smith et al., 1995). The most consistent
ﬁnding seems to be an increase in total PME in the prefrontal cortex in
AD compared with elderly controls (Cuenod et al., 1995; Forlenza et al.,
2005; Pettegrew et al., 1994). In the present study, part of the frontal
cortex was covered in the ACC measurement, but we did not ﬁnd
changes in PEth, PCh, nor total PME. However, changes in the complex
phospholipid cycle may be too small at this disease stage to be detected
with the current methodology. Although we had suﬃcient spectral re-
solution to resolve the phosphomonoester signal of PEth and PCh, and
the phosphodiesters signal of GPEth and GPCh, these may still reﬂect
metabolites connected to diﬀerent phospholipid pools. Moreover, dif-
ferential expression of phosphatidylethanolamine and phosphati-
dylcholine species across hippocampal subﬁelds was recently shown in
AD (Mendis et al., 2016).
MRSI revealed that high energy phosphates, pH and most phos-
pholipid metabolites vary extensively across brain regions that are of
interest in AD. These diﬀerences existed in both mild AD patients and
controls, and were not explained by regional variation in grey and
white matter content, with the ratio PCr/Pi as the sole exception. This
indicates that the investigated regions are metabolically diﬀerent from
each other. It also underlines that regional diﬀerences should be taken
into account in any cross-sectional or longitudinal metabolic study.
Moreover, as shown here for PCr, changes in metabolite levels in dis-
ease may not be the same for all brain regions.
The current study only reports on relative metabolite levels, as
obtaining absolute quantiﬁcations requires several assumptions, which
adds complexity and reduces reliability. Moreover, when the variation
in atrophy between and within groups is large, relative measurements
are preferred over absolute. A second limitation may be that our results
have not been corrected for multiple testing, because of the exploratory
nature of this study. Replication of these results in an independent
population would strengthen our ﬁndings. In future research it would
be valuable to include preclinical AD patients or an at-risk population
to clarify the disease stage in which abnormalities in PCr and pH ap-
pear, as well as perform longitudinal (intervention) studies to follow
these abnormalities. In addition, magnetization transfer experiments to
determine the CK and ATPase reaction rates with measurements of
absolute concentrations of PCr and ATP to determine ﬂuxes (Du et al.,
2007), would elucidate whether the dynamics of the PCr-CK and AT-
Pases systems are aﬀected in AD.
4.1. Conclusion
To the best of our knowledge, this is the largest study to date in-
vestigating brain phospholipid and energy metabolism in AD by 31P
MRS. Increased PCr levels were found in regions that show early de-
generation in AD, but not in the ACC, a region known to be involved in
this disease at a later stage. Together with an increased pH, this in-
dicates that energy metabolism is altered in mild AD. Although most
Fig. 3. Normalized phosphocreatine (PCr; A), ratio of PCr to inorganic phosphate (PCr/
Pi; B) and pH (C) in patients with Alzheimer's disease (AD) and healthy control (HC)
subjects. PCr was normalized by expressing the integral as a percent area of the total
phosphorous signal in the corresponding spectrum. Data represent Least Square
means± SEM, *p < 0.05 AD vs HC. ACC, anterior cingulate cortex; RSC, retrosplenial
cortex; HL, left hippocampus; HR, right hippocampus.
Table 2
Main eﬀect of group (healthy controls vs Alzheimer's disease) on phosphorus metabolite
signals and tissue pH for all investigated regions.
AD Control p-Value
PCr* 19.04 ± 0.18
n= 124
18.08 ± 0.18
n=124
<0.001
Pi 5.30 ± 0.11
n= 121
5.47 ± 0.11
n=123
0.240
PCr/Pi 3.71 ± 0.09
n= 121
3.49 ± 0.09
n=123
0.046
total ATP 42.88 ± 0.27
n= 124
43.17 ± 0.27
n=124
0.445
NAD(H) 3.96 ± 0.11
n= 103
4.09 ± 0.11
n=96
0.388
PEth 8.19 ± 0.11
n= 119
8.33 ± 0.11
n=122
0.375
PCh 3.90 ± 0.07
n= 112
3.93 ± 0.07
n=114
0.757
GPEth 4.32 ± 0.11
n= 109
4.31 ± 0.11
n=117
0.942
GPCh 5.96 ± 0.15
n= 108
6.08 ± 0.15
n=109
0.526
pH 7.037 ± 0.003
n= 121
7.028 ± 0.003
n=123
0.032
LS means ± SEM of metabolite levels, as percentage of total phosphorus signal in the
corresponding spectrum, in patients with Alzheimer's disease and healthy control sub-
jects. Signiﬁcant group eﬀects (p < 0.05, AD versus Control) indicated in bold. *PCr also
has a signiﬁcant interaction between group and brain region. LS, least squares; SEM,
standard error of the mean; n, number of observations; AD, Alzheimer's disease; HC,
healthy control; PCr, Phosphocreatine; Pi, inorganic phosphate; ATP, adenosine tripho-
sphate; NAD(H), nicotinamide adenine dinucleotide; PEth, phosphoethanolamine; PCh,
phosphocholine; GPEth, glycerophosphoethanolamine; GPCh, glycerophosphocholine.
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phospholipid metabolites, like the high energy phosphates, diﬀered
between the investigated brain regions in both groups, no alterations in
phospholipid metabolism were found speciﬁc to mild AD.
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